BIOMARIN PHARMACEUTICAL INC - Common Stock, par value $0.001 per share (BMRN) Institutional Ownership

13F Institutional Holders and Ownership History from Q1 2014 to Q4 2025

Type / Class
Equity / Common Stock, par value $0.001 per share
Symbol
BMRN on Nasdaq
Shares outstanding
193,539,047
Price per share
$59.43
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
179,354,044
Total reported value
$9,713,819,570
% of total 13F portfolios
0.01%
Share change
-4,815,551
Value change
-$263,756,700
Number of holders
569
Price from insider filings
$59.43
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of BIOMARIN PHARMACEUTICAL INC - Common Stock, par value $0.001 per share (BMRN) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BlackRock, Inc. 11% $1,225,457,238 20,620,179 BlackRock, Inc. 31 Mar 2025
PRIMECAP MANAGEMENT CO/CA/ 8.2% $925,293,536 15,795,383 PRIMECAP MANAGEMENT CO/CA/ 30 Jun 2025
Capital Research Global Investors 4.8% -29% $543,823,427 -$228,277,583 9,150,655 -30% Capital Research Global Investors 31 Mar 2025
VIKING GLOBAL INVESTORS LP 4.3% -35% $450,729,215 -$214,821,957 8,322,179 -32% VIKING GLOBAL INVESTORS LP 30 Sep 2025

As of 30 Sep 2025, 569 institutional investors reported holding 179,354,044 shares of BIOMARIN PHARMACEUTICAL INC - Common Stock, par value $0.001 per share (BMRN). This represents 93% of the company’s total 193,539,047 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of BIOMARIN PHARMACEUTICAL INC - Common Stock, par value $0.001 per share (BMRN) together control 65% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
BlackRock, Inc. 11% 22,046,050 -8.1% 0.02% $1,194,014,041
VANGUARD GROUP INC 9.6% 18,582,585 -2.2% 0.02% $1,006,432,803
PRIMECAP MANAGEMENT CO/CA/ 7.9% 15,229,287 -3.4% 0.63% $824,818,238
Dodge & Cox 7.6% 14,686,801 -2.8% 0.43% $795,437,142
STATE STREET CORP 4.5% 8,764,599 -0.94% 0.02% $474,690,682
VIKING GLOBAL INVESTORS LP 4.3% 8,322,179 -32% 1.2% $450,729,215
AQR CAPITAL MANAGEMENT LLC 3.1% 5,932,109 +6.3% 0.21% $321,283,017
GEODE CAPITAL MANAGEMENT, LLC 1.8% 3,542,120 +1.9% 0.01% $191,287,006
MILLENNIUM MANAGEMENT LLC 1.4% 2,627,210 -7.3% 0.11% $142,289,694
Capital Research Global Investors 1.3% 2,537,596 +548% 0.03% $137,436,199
GOLDMAN SACHS GROUP INC 1.2% 2,290,960 +8.8% 0.02% $124,078,425
DIMENSIONAL FUND ADVISORS LP 1.2% 2,245,186 +43% 0.03% $121,596,850
RENAISSANCE TECHNOLOGIES LLC 0.98% 1,893,571 +4.8% 0.14% $102,555,805
NORTHERN TRUST CORP 0.86% 1,662,268 +0.43% 0.01% $90,028,434
UBS Group AG 0.8% 1,540,170 -9.2% 0.02% $83,415,608
Man Group plc 0.77% 1,493,379 +1.1% 0.16% $80,881,406
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.72% 1,397,600 -10% 0.01% $75,694,016
Squarepoint Ops LLC 0.72% 1,388,524 -17% 0.16% $75,202,460
MORGAN STANLEY 0.71% 1,380,444 -43% 0% $74,764,966
Bank of New York Mellon Corp 0.71% 1,372,436 +0.5% 0.01% $74,331,156
LOS ANGELES CAPITAL MANAGEMENT LLC 0.69% 1,332,398 +379% 0.24% $72,162,676
DNB ASSET MANAGEMENT AS 0.66% 1,274,284 +14% 0.26% $69,015,221
AMERIPRISE FINANCIAL INC 0.63% 1,228,662 -43% 0.02% $66,543,522
DEUTSCHE BANK AG\ 0.56% 1,085,983 +22% 0.02% $58,816,839
UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC 0.56% 1,074,173 -19% 0.01% $58,177,212

Institutional Holders of BIOMARIN PHARMACEUTICAL INC - Common Stock, par value $0.001 per share (BMRN) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 2,090,096 $124,275,609 +$82,562,267 $59.43 19
2025 Q3 179,354,044 $9,713,819,570 -$263,756,700 $54.16 569
2025 Q2 184,517,421 $10,145,314,664 +$90,429,312 $54.97 577
2025 Q1 181,019,333 $12,788,693,274 -$83,694,968 $70.69 575
2024 Q4 183,168,073 $12,040,351,377 +$366,896,664 $65.73 531
2024 Q3 176,742,856 $12,420,524,467 -$694,012,695 $70.29 545
2024 Q2 184,954,617 $15,225,773,378 +$201,460,753 $82.33 551
2024 Q1 183,434,463 $16,022,131,923 -$290,198,804 $87.34 549
2023 Q4 1,575,634 $152,003,757 +$8,466,779 $96.42 8
2023 Q3 177,272,431 $15,681,861,571 +$286,097,941 $88.48 498
2023 Q2 172,250,293 $14,939,059,054 -$351,903,439 $86.68 535
2023 Q1 175,802,779 $17,084,653,104 -$406,194,792 $97.24 534
2022 Q4 181,827,820 $18,828,888,382 +$42,443,716 $103.49 561
2022 Q3 180,672,593 $15,322,765,819 +$296,171,565 $84.77 521
2022 Q2 178,054,655 $14,741,643,357 +$129,399,259 $82.87 513
2022 Q1 175,063,077 $13,501,487,760 +$11,607,220 $77.10 528
2021 Q4 174,767,020 $15,435,756,007 +$129,263,062 $88.35 530
2021 Q3 175,028,482 $13,525,852,754 +$32,397,316 $77.29 493
2021 Q2 173,968,307 $14,512,680,442 -$128,727,084 $83.44 502
2021 Q1 174,820,418 $13,198,809,499 -$350,185,260 $75.51 508
2020 Q4 179,660,807 $15,744,104,520 +$287,321,913 $87.69 510
2020 Q3 178,662,635 $13,588,352,315 -$311,952,831 $76.08 476
2020 Q2 179,930,016 $22,185,209,979 +$736,875,977 $123.34 507
2020 Q1 174,268,886 $14,724,694,356 +$280,864,206 $84.50 476
2019 Q4 172,914,105 $14,614,939,863 +$51,119,556 $84.55 446
2019 Q3 173,340,933 $11,682,517,683 -$330,416,789 $67.40 418
2019 Q2 177,654,024 $15,212,261,178 +$318,332,031 $85.65 465
2019 Q1 178,050,816 $15,815,533,803 -$68,839,949 $88.83 468
2018 Q4 178,825,880 $15,227,433,663 -$188,309,907 $85.15 451
2018 Q3 180,863,772 $17,539,420,449 -$163,693,309 $96.97 442
2018 Q2 182,661,683 $17,204,796,967 +$326,968,761 $94.20 433
2018 Q1 179,361,480 $14,541,631,463 +$216,945,038 $81.07 414
2017 Q4 176,080,399 $15,699,149,954 +$261,832,543 $89.17 424
2017 Q3 174,770,792 $16,264,267,189 +$327,967,062 $93.07 402
2017 Q2 168,744,764 $15,320,874,144 +$170,637,441 $90.82 416
2017 Q1 168,965,848 $14,832,721,260 +$934,215,612 $87.78 407
2016 Q4 169,392,619 $14,033,164,313 +$54,304,052 $82.84 403
2016 Q3 168,155,271 $15,553,010,289 +$820,607,801 $92.52 417
2016 Q2 158,435,858 $12,340,944,606 -$246,368,811 $77.80 383
2016 Q1 161,468,419 $13,315,040,263 +$259,764,227 $82.48 373
2015 Q4 166,229,048 $16,897,740,727 +$174,387,985 $104.76 381
2015 Q3 159,370,335 $16,783,252,713 +$90,263,867 $105.32 385
2015 Q2 155,703,305 $21,299,007,632 +$181,688,405 $136.78 388
2015 Q1 156,505,212 $19,499,122,209 +$1,280,086,163 $124.62 373
2014 Q4 147,575,254 $13,343,784,993 +$113,073,044 $90.40 336
2014 Q3 147,667,828 $10,655,377,287 +$240,822,124 $72.16 312
2014 Q2 143,948,797 $8,955,289,726 -$420,228,703 $62.21 318
2014 Q1 146,683,929 $10,001,777,849 +$474,022,275 $68.21 307